Biologics, small molecules, steroids, biosimilars, approvals, and treatment access updates.
Page 7 of 26 · 1221 articles
This label update affects people with IBD because golimumab (SIMPONI) is an approved anti‑TNF treatment for ulcerative colitis and the label includes safety changes and pediatric dosing information that could affect...
Patients receiving immune checkpoint inhibitors can develop ICI‑induced colitis that resembles IBD and may not respond to steroids. This review discusses advanced biologic and targeted therapies used when steroids fail,...
This review highlights a plant-derived compound, ferulic acid, that showed anti-colitis effects in experimental studies, suggesting a potential new adjunctive therapy pathway worth watching for future clinical research.
This study provides real-world evidence about using upadacitinib as a maintenance therapy in children with refractory Crohn’s disease — a group with limited treatment options.
This study compares bloodstream infection risk across commonly used biologics for IBD, which could affect decisions about choosing or monitoring biologic therapy. It also highlights that steroid co-use may increase...
This post‑marketing study will add safety and real‑world effectiveness information about Tabellvi® (adalimumab) in Chinese adults with moderate to severe Crohn's disease, which can inform patients and clinicians using or...
The study suggests active smoking reduces the effectiveness of anti-TNF biologics in people with IBD, which could affect treatment response and the need to switch or escalate therapies. This supports including smoking...
Patients and clinicians often face trade-offs when managing overlapping immune-mediated diseases. This report shows how past thromboembolic events and disease remission status can steer therapy away from JAK inhibitors...
Dose increases are common during IBD maintenance and vary a lot by drug and patient profile. Knowing which treatments and patient factors are linked to escalation can help patients and clinicians plan monitoring and...
This pooled analysis compares serious-infection and sepsis risks across advanced therapies used in immune-mediated inflammatory diseases, including IBD. It suggests JAK inhibitors are linked to higher serious-infection...
Perianal fistulising Crohn's disease is hard to treat and often fails anti-TNF drugs. This study will provide real-world data on whether upadacitinib can be effective and safe for patients with refractory perianal...
This study compares two commonly used biologics as first-line therapy for moderate-to-severe ulcerative colitis and reports better short- and long-term effectiveness for vedolizumab with similar safety. The results could...
Depression before an IBD diagnosis was linked to more early treatment escalation and acute-care use after diagnosis. Recognizing preexisting depression could help clinicians identify patients who may benefit from closer...
Real-world registry data on upadacitinib can help patients and clinicians understand how the drug performs outside clinical trials, including patterns of use, effectiveness, and safety over time.
Persistent diarrhea is a common, quality-of-life–limiting problem in ulcerative colitis; this review synthesizes how epithelial transport, barrier damage, immune signaling, mitochondria, and microbiota interact and...
People with IBD or their clinicians may worry that systemic antifungal treatment could trigger flares.
This study compares two JAK inhibitors (upadacitinib and tofacitinib) used as rescue therapy for acute severe ulcerative colitis and reports lower 1‑year colectomy rates with upadacitinib. That could influence choices...
Identifying a genetic cause (XIAP frameshift variant) helped explain why anti‑TNF drugs failed and why blocking IL‑12/23 with ustekinumab led to improvement; that connection could influence treatment choices for similar...
Regulatory approvals and trial activity for upadacitinib (Rinvoq) affect availability and prescribing patterns for immunomodulatory treatment options used across autoimmune and inflammatory diseases, including IBD.
Early prediction of who will not respond to infliximab could help clinicians avoid prolonged ineffective treatment, enabling earlier reassessment and changes in therapy as part of treat-to-target care.
Researchers have found a short peptide in potato protein with antioxidant and anti-inflammatory properties and are testing it as a possible oral treatment for intestinal inflammation — a potential new, plant-derived...
IL-23 inhibitors are a newer class of biologics for moderate-to-severe ulcerative colitis that may offer another effective option for patients who have not responded to existing therapies, with improving evidence for...
Patients and clinicians often need evidence about whether switching from ustekinumab to an anti‑TNF (infliximab or adalimumab) still gives meaningful clinical responses. This study suggests many patients can respond, but...
Refractory IBD in children is linked to growth and development problems, hospitalizations, and surgery; knowing treatment options after anti‑TNF failure matters for long‑term outcomes. The review highlights which...
Based on the title and source metadata, this appears to be a clinical study related to Ustekinumab, IL-12/23 inhibitor, and Medications. The original article is from idp.nature.com.
FDA IND clearance lets PALI‑2108 move into a Phase 2 trial in Crohn’s disease, meaning the drug’s safety and efficacy will be formally tested in people with moderate-to-severe disease. The program is being run alongside...
This study directly compares two rescue medications used when intravenous steroids fail in acute severe ulcerative colitis, reporting similar short-term remission and safety but a slower early response with tacrolimus —...
This study gives real-world 52‑week data on upadacitinib maintenance in children with refractory Crohn's disease, showing meaningful remission rates but also notable adverse events. That balance is important for families...
Orofacial granulomatosis often co-occurs with Crohn's disease and appears linked to a distinct Crohn's phenotype and treatment needs. The findings suggest that advanced therapies can be effective for OFG-associated CD...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Sulfasalazine. The original article is from Pediatric Gastroenterology,...
Preclinical data suggest blocking STAT3 with TTI-101 prevented colitis-associated colorectal tumors in a mouse model and altered tumor-related gene expression and the gut microbiome — findings that could guide future...
Based on the title and source metadata, this appears to be a systematic review or meta analysis related to Inflammatory bowel disease and Research and clinical trials. The original article is from Frontiers in...
FDA clearance lets Palisade start a Phase 2 trial of PALI-2108 in moderate-to-severe Crohn’s disease, which could matter to patients and clinicians watching new oral treatments targeted to the lower intestine.
A new oral investigational drug (TP317) is entering a Phase 1b study in adults with active UC to assess safety and pharmacokinetics, which may be relevant to patients seeking information about emerging therapies.
Biologics can be critical for treating moderate-to-severe IBD, but cost and treatment failure limit access and long‑term use in this Indian cohort. Understanding uptake and reasons for stopping helps target interventions...
A formulation that increases oral absorption of quercetin and reduces inflammation in animal models could point toward new flavonoid-based therapies for ulcerative colitis, but findings are preclinical.
The study compares ustekinumab effectiveness between biologic‑naïve and biologic‑experienced Crohn’s patients and links clinical response to better quality of life and reduced anxiety — information relevant when...
This meta-analysis pulls together early trial evidence that TL1A antagonists may improve clinical, endoscopic, and histologic outcomes in both UC and CD and reports an overall acceptable short-term safety...
A randomized trial tested whether adding dapagliflozin (an SGLT2 inhibitor) to mesalamine changes disease activity in adults with mild–moderate ulcerative colitis over 6 months. If effective and safe, it could suggest a...
Patients and clinicians using ustekinumab may be able to use an early (around 3 months) drug concentration to help predict short-term remission, while routine repeated monitoring later on may be less informative for...
This highlights a new, biologically distinct drug target (IL‑7Rα) in ulcerative colitis that may help patients who do not respond to existing biologics, and it summarizes early clinical evidence for lusvertikimab while...
The project investigates how TNFR1 and TNFR2 differently control epithelial repair in the colon—mechanisms that may explain why many patients on anti‑TNF biologics do not achieve lasting mucosal healing and could point...
This project describes a novel off-the-shelf engineered regulatory T cell therapy aiming to promote intestinal immune regulation and mucosal healing — a different approach than current biologics. If successful, it could...
The paper identifies epothilone B as a repurposing candidate that may reduce neutrophil-driven inflammation and support epithelial healing in IBD models, a potential new strategy distinct from broad neutrophil...
The study identifies epithelial IFN‑I signaling as a driver of barrier failure in anti‑TNF refractory Crohn’s disease and suggests that blocking IFN‑I could be a rescue strategy for patients who do not respond to...
This large national-registry study identifies clinical features linked with needing optimization of biologic or small-molecule therapies in CD and UC. That helps show which patient groups more often require...
The study suggests starting anti-TNF therapy with an immunomodulator at diagnosis may reduce surgery, hospital stays, and progression to complicated Crohn’s over 5 years — outcomes that matter to patients and clinicians...
Shifting care toward disease modification could reduce long-term bowel damage and disability for people with Crohn's disease by prioritizing earlier, more effective treatment and exploring prevention strategies.
